GATA-6 and NF-κB activate CPI-17 gene transcription and regulate ca2+ sensitization of smooth muscle contraction

Molecular and Cellular Biology

Volumn 33, Issue 5, 2013, Pages 1085-1102

  Boopathi, Ettickan ^a   Hypolite, Joseph A ^a   Zderic, Stephen A ^b   Gomes, Cristiano Mendes ^c   Malkowicz, Bruce ^a   Liou, Hsiou Chi ^d   Wein, Alan J ^a   Chacko, Samuel ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

^d WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM ION; CPI 17 PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN; TRANSCRIPTION FACTOR GATA 6; TRANSCRIPTION FACTOR REL; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING SITE; BLADDER HYPERTROPHY; BLADDER NECK STENOSIS; CHROMATIN IMMUNOPRECIPITATION; COLUMN CHROMATOGRAPHY; CONTROLLED STUDY; DNA FLANKING REGION; GENE SILENCING; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; KNOCKOUT MOUSE; MALE; MOUSE; MUSCLE CONTRACTION; MUSCLE HYPERTROPHY; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE HYPERTROPHY; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN MOTIF; PROTEIN PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION; SMOOTH MUSCLE FIBER; TATA BOX; UPREGULATION; WILD TYPE;

ANIMALS; BASE SEQUENCE; CALCIUM; CELLS, CULTURED; CONSERVED SEQUENCE; GATA6 TRANSCRIPTION FACTOR; GENE KNOCKOUT TECHNIQUES; HUMANS; HYPERTROPHY; MALE; MICE; MICE, KNOCKOUT; MUSCLE CONTRACTION; MUSCLE PROTEINS; MUSCLE, SMOOTH; NF-KAPPA B; PHOSPHOPROTEIN PHOSPHATASES; PHOSPHOPROTEINS; PROMOTER REGIONS, GENETIC; RNA INTERFERENCE; UP-REGULATION; URINARY BLADDER; URINARY BLADDER NECK OBSTRUCTION;

EID: 84874704264     PISSN: 02707306     EISSN: 10985549     Source Type: Journal    
DOI: 10.1128/MCB.00626-12     Document Type: Article

References (74)

1. Adelstein RS, Eisenberg E. 1980. Regulation and kinetics of the actinmyosin- ATP interaction. Annu. Rev. Biochem. 49:921-956.
2. Somlyo AP, Somlyo AV. 2003. Ca2+ sensitivity of smooth muscle and nonmuscle myosin II: modulated by G proteins, kinases, and myosin phosphatase. Physiol. Rev. 83:1325-1358.
3. Somlyo AP, Somlyo AV. 2000. Signal transduction by G-proteins, rhokinase and protein phosphatase to smooth muscle and non-muscle myosin II. J. Physiol. 522(Pt 2):177-185.
4. Mizuno Y, Isotani E, Huang J, Ding H, Stull JT, Kamm KE. 2008. Myosin light chain kinase activation and calcium sensitization in smooth muscle in vivo. Am. J. Physiol. Cell Physiol. 295:C358 -C364.
5. Wang T, Kendig DM, Smolock EM, Moreland RS. 2009. Carbacholinduced rabbit bladder smooth muscle contraction: roles of protein kinase C and Rho kinase. Am. J. Physiol. Renal Physiol. 297:F1534 -F1542.
6. Woodsome TP, Eto M, Everett A, Brautigan DL, Kitazawa T. 2001. Expression of CPI-17 and myosin phosphatase correlates with Ca(2+) sensitivity of protein kinase C-induced contraction in rabbit smooth muscle. J. Physiol. 535:553-564.
7. Eto M, Bock R, Brautigan DL, Linden DJ. 2002. Cerebellar long-term synaptic depression requires PKC-mediated activation of CPI-17, a myosin/moesin phosphatase inhibitor. Neuron 36:1145-1158.
8. Eto M, Ohmori T, Suzuki M, Furuya K, Morita F. 1995. A novel protein phosphatase-1 inhibitory protein potentiated by protein kinase C. Isolation from porcine aorta media and characterization. J. Biochem. 118: 1104-1107.
9. Eto M, Senba S, Morita F, Yazawa M. 1997. Molecular cloning of a novel phosphorylation-dependent inhibitory protein of protein phosphatase-1 (CPI17) in smooth muscle: its specific localization in smooth muscle. FEBS Lett. 410:356-360.
10. Ohama T, Hori M, Sato K, Ozaki H, Karaki H. 2003. Chronic treatment with interleukin-1beta attenuates contractions by decreasing the activities of CPI-17 and MYPT-1 in intestinal smooth muscle. J. Biol. Chem. 278: 48794-48804.
11. Sakai H, Chiba Y, Hirano T, Misawa M. 2005. Possible involvement of CPI-17 in augmented bronchial smooth muscle contraction in antigen- induced airway hyper-responsive rats. Mol. Pharmacol. 68:145-151.
12. Dakshinamurti S, Mellow L, Stephens NL. 2005. Regulation of pulmonary arterial myosin phosphatase activity in neonatal circulatory transition and in hypoxic pulmonary hypertension: a role for CPI-17. Pediatr. Pulmonol. 40:398-407.
13. Eto M, Kitazawa T, Yazawa M, Mukai H, Ono Y, Brautigan DL. 2001. Histamine-induced vasoconstriction involves phosphorylation of a specific inhibitor protein for myosin phosphatase by protein kinase C alpha and delta isoforms. J. Biol. Chem. 276:29072-29078.
14. Chang S, Hypolite JA, DiSanto ME, Changolkar A, Wein AJ, Chacko S. 2006. Increased basal phosphorylation of detrusor smooth muscle myosin in alloxan-induced diabetic rabbit is mediated by upregulation of Rho-kinase beta and CPI-17. Am. J. Physiol. Renal Physiol. 290: F650 -F656.
15. Xie Z, Su W, Guo Z, Pang H, Post SR, Gong MC. 2006. Upregulation of CPI-17 phosphorylation in diabetic vasculature and high glucose cultured vascular smooth muscle cells. Cardiovasc. Res. 69: 491-501.
16. Chang S, Hypolite JA, Mohanan S, Zderic SA, Wein AJ, Chacko S. 2009. Alteration of the PKC-mediated signaling pathway for smooth muscle contraction in obstruction-induced hypertrophy of the urinary bladder. Lab. Invest. 89:823-832.
17. Jin H, Sperka T, Herrlich P, Morrison H. 2006. Tumorigenic transformation by CPI-17 through inhibition of a merlin phosphatase. Nature 442:576-579.
18. Hu W, Mahavadi S, Li F, Murthy KS. 2007. Upregulation of RGS4 and downregulation of CPI-17 mediate inhibition of colonic muscle contraction by interleukin-1beta. Am. J. Physiol. Cell Physiol. 293: C1991-C2000.
19. Kim JI, Urban M, Young GD, Eto M. 2012. Reciprocal regulation controlling the expression of CPI-17, a specific inhibitor protein for the myosin light chain phosphatase in vascular smooth muscle cells. Am. J. Physiol. Cell Physiol. 303:C58 -C68.
20. Boopathi E, Gomes CM, Goldfarb R, John M, Srinivasan VG, Alanzi J, Malkowicz SB, Kathuria H, Zderic SA, Wein AJ, Chacko S. 2011. Transcriptional repression of caveolin-1 (CAV1) gene expression by GATA-6 in bladder smooth muscle hypertrophy in mice and human beings. Am. J. Pathol. 178:2236-2251.
21. Thompson JD, Higgins DG, Gibson TJ. 1994. CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res. 22:4673-4680.
22. Austin JC, Chacko SK, DiSanto M, Canning DA, Zderic SA. 2004. A male murine model of partial bladder outlet obstruction reveals changes in detrusor morphology, contractility and myosin isoform expression. J. Urol. 172:1524-1528.
23. Masternak K, Muhlethaler-Mottet A, Villard J, Zufferey M, Steimle V, Reith W. 2000. CIITA is a transcriptional coactivator that is recruited to MHC class II promoters by multiple synergistic interactions with an enhanceosome complex. Genes Dev. 14:1156-1166.
24. Kadonaga JT, Tjian R. 1986. Affinity purification of sequence-specific DNA binding proteins. Proc. Natl. Acad. Sci. U. S. A. 83:5889-5893.
25. Dignam JD, Lebovitz RM, Roeder RG. 1983. Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei. Nucleic Acids Res. 11:1475-1489.
26. Singh H, Sen R, Baltimore D, Sharp PA. 1986. A nuclear factor that binds to a conserved sequence motif in transcriptional control elements of immunoglobulin genes. Nature 319:154-158.
27. Boopathi E, Lenka N, Prabu SK, Fang JK, Wilkinson F, Atchison M, Giallongo A, Avadhani NG. 2004. Regulation of murine cytochrome c oxidase Vb gene expression during myogenesis: YY-1 and heterogeneous nuclear ribonucleoprotein D-like protein (JKTBP1) reciprocally regulate transcription activity by physical interaction with the BERF-1/ZBP-89 factor. J. Biol. Chem. 279:35242-35254.
28. O'Neill LP, Turner BM. 1995. Histone H4 acetylation distinguishes coding regions of the human genome from heterochromatin in a differentiation- dependent but transcription-independent manner. EMBO J. 14: 3946-3957.
29. Polyak E, Boopathi E, Mohanan S, Deng M, Zderic SA, Wein AJ, Chacko S. 2009. Alterations in caveolin expression and ultrastructure after bladder smooth muscle hypertrophy. J. Urol. 182:2497-2503.
30. Schreiber E, Matthias P, Muller MM, Schaffner W. 1989. Rapid detection of octamer binding proteins with 'mini-extracts,' prepared from a small number of cells. Nucleic Acids Res. 17:6419. 31. Anderson DJ, Blobel G. 1983. Immunoprecipitation of proteins from cell-free translations. Methods Enzymol. 96:111-120.
31. Anderson DJ, Blobel G. 1983. Immunoprecipitation of proteins from cell-free translations. Methods Enzymol. 96:111-120.
32. Zhang EY, Stein R, Chang S, Zheng Y, Zderic SA, Wein AJ, Chacko S. 2004. Smooth muscle hypertrophy following partial bladder outlet obstruction is associated with overexpression of non-muscle caldesmon. Am. J. Pathol. 164:601-612.
33. Hypolite JA, Chang S, LaBelle E, Babu GJ, Periasamy M, Wein AJ, Chacko S. 2009. Deletion of SM-B, the high ATPase isoform of myosin, upregulates the PKC-mediated signal transduction pathway in murine urinary bladder smooth muscle. Am. J. Physiol. Renal Physiol. 296:F658-F665.
34. Hypolite JA, DiSanto ME, Zheng Y, Chang S, Wein AJ, Chacko S. 2001. Regional variation in myosin isoforms and phosphorylation at the resting tone in urinary bladder smooth muscle. Am. J. Physiol. Cell Physiol. 280: C254-C264.
35. Stanton MC, Delaney D, Zderic SA, Moreland RS. 2004. Partial bladder outlet obstruction abolishes the receptor- and G protein-dependent increase in calcium sensitivity in rabbit bladder smooth muscle. Am. J. Physiol. Renal Physiol. 287:F682-F689.
36. Fabiato A. 1988. Computer programs for calculating total from specified free or free from specified total ionic concentrations in aqueous solutions containing multiple metals and ligands. Methods Enzymol. 157:378 - 417.
37. Moreland RS, Murphy RA. 1986. Determinants of Ca2+-dependent stress maintenance in skinned swine carotid media.Am.J. Physiol. 251:C892-C903.
38. Cartharius K, Frech K, Grote K, Klocke B, Haltmeier M, Klingenhoff A, Frisch M, Bayerlein M, Werner T. 2005. MatInspector and beyond: promoter analysis based on transcription factor binding sites. Bioinformatics 21:2933-2942.
39. Wang T, Kendig DM, Trappanese DM, Smolock EM, Moreland RS. 2012. Phorbol 12,13-dibutyrate-induced, protein kinase C-mediated contraction of rabbit bladder smooth muscle. Front. Pharmacol. 2:83. doi:10.3389/fphar.2011.00083.
40. Fulginiti J, III, Singer HA, Moreland RS. 1993. Phorbol ester-induced contractions of swine carotid artery are supported by slowly cycling crossbridges which are not dependent on calcium or myosin light chain phosphorylation. J. Vasc. Res. 30:315-322.
41. Abrams P, Donovan JL, de la Rosette JJ, Schafer W. 1997. International Continence Society "Benign Prostatic Hyperplasia" study: background, aims, and methodology. Neurourol. Urodyn. 16:79-91.
42. Levin RM, Haugaard N, O'Connor L, Buttyan R, Das A, Dixon JS, Gosling JA. 2000. Obstructive response of human bladder to BPH vs. rabbit bladder response to partial outlet obstruction: a direct comparison. Neurourol. Urodyn. 19:609-629.
43. Bing W, Chang S, Hypolite JA, DiSanto ME, Zderic SA, Rolf L, Wein AJ, Chacko S. 2003. Obstruction-induced changes in urinary bladder smooth muscle contractility: a role for Rho kinase. Am. J. Physiol. Renal Physiol. 285:F990 -F997.
44. Chang S, Gomes CM, Hypolite JA, Marx J, Alanzi J, Zderic SA, Malkowicz B, Wein AJ, Chacko S. 2010. Detrusor overactivity is associated with downregulation of large-conductance calcium- and voltageactivated potassium channel protein. Am. J. Physiol. Renal Physiol. 298: F1416-F1423.
45. Clement MR, Delaney DP, Austin JC, Sliwoski J, Hii GC, Canning DA, DiSanto ME, Chacko SK, Zderic SA. 2006. Activation of the calcineurin pathway is associated with detrusor decompensation: a potential therapeutic target. J. Urol. 176:1225-1229.
46. DiSanto ME, Stein R, Chang S, Hypolite JA, Zheng Y, Zderic S, Wein AJ, Chacko S. 2003. Alteration in expression of myosin isoforms in detrusor smooth muscle following bladder outlet obstruction. Am. J. Physiol. Cell Physiol. 285:C1397-C1410.
47. Baeuerle PA, Baltimore D. 1996. NF-kappa B: ten years after. Cell 87:13-20.
48. Gaspar-Pereira S, Fullard N, Townsend PA, Banks PS, Ellis EL, Fox C, Maxwell AG, Murphy LB, Kirk A, Bauer R, Caamano JH, Figg N, Foo RS, Mann J, Mann DA, Oakley F. 2012. The NF-kappaB subunit c-Rel stimulates cardiac hypertrophy and fibrosis. Am. J. Pathol. 180:929-939.
49. Karin M, Lin A. 2002. NF-kappaB at the crossroads of life and death. Nat. Immunol. 3:221-227.
50. Shaw J, Yurkova N, Zhang T, Gang H, Aguilar F, Weidman D, Scramstad C, Weisman H, Kirshenbaum LA. 2008. Antagonism of E2F-1 regulated Bnip3 transcription by NF-kappaB is essential for basal cell survival. Proc. Natl. Acad. Sci. U. S. A. 105:20734-20739.
51. Ohama T, Hori M, Momotani E, Iwakura Y, Guo F, Kishi H, Kobayashi S, Ozaki H. 2007. Intestinal inflammation downregulates smooth muscle CPI-17 through induction of TNF-alpha and causes motility disorders. Am. J. Physiol. Gastrointest. Liver Physiol. 292: G1429 -G1438.
52. Cogswell JP, Godlevski MM, Wisely GB, Clay WC, Leesnitzer LM, Ways JP, Gray JG. 1994. NF-kappa B regulates IL-1 beta transcription through a consensus NF-kappa B binding site and a nonconsensus CRElike site. J. Immunol. 153:712-723.
53. Karin M. 1999. The beginning of the end: IkappaB kinase (IKK) and NF-kappaB activation. J. Biol. Chem. 274:27339-27342.
54. Purcell NH, Tang G, Yu C, Mercurio F, DiDonato JA, Lin A. 2001. Activation of NF-kappa B is required for hypertrophic growth of primary rat neonatal ventricular cardiomyocytes. Proc. Natl. Acad. Sci. U. S. A. 98:6668-6673.
55. Evans T, Reitman M, Felsenfeld G. 1988. An erythrocyte-specific DNAbinding factor recognizes a regulatory sequence common to all chicken globin genes. Proc. Natl. Acad. Sci. U. S. A. 85:5976-5980.
56. Orkin SH. 1992. GATA-binding transcription factors in hematopoietic cells. Blood 80:575-581.
57. Burch JB. 2005. Regulation of GATA gene expression during vertebrate development. Semin. Cell Dev. Biol. 16:71-81.
58. Kanematsu A, Ramachandran A, Adam RM. 2007. GATA-6 mediates human bladder smooth muscle differentiation: involvement of a novel enhancer element in regulating alpha-smooth muscle actin gene expression. Am. J. Physiol. Cell Physiol. 293:C1093-C1102.
59. Lien CL, Wu C, Mercer B, Webb R, Richardson JA, Olson EN. 1999. Control of early cardiac-specific transcription of Nkx2-5 by a GATAdependent enhancer. Development 126:75-84.
60. Molkentin JD. 2000. The zinc finger-containing transcription factors GATA-4, -5, and -6. Ubiquitously expressed regulators of tissue-specific gene expression. J. Biol. Chem. 275:38949-38952.
61. Molkentin JD, Tymitz KM, Richardson JA, Olson EN. 2000. Abnormalities of the genitourinary tract in female mice lacking GATA5. Mol. Cell. Biol. 20:5256-5260.
62. Oh J, Wang Z, Wang DZ, Lien CL, Xing W, Olson EN. 2004. Target gene-specific modulation of myocardin activity by GATA transcription factors. Mol. Cell. Biol. 24:8519-8528.
63. Xin M, Davis CA, Molkentin JD, Lien CL, Duncan SA, Richardson JA, Olson EN. 2006. A threshold of GATA4 and GATA6 expression is required for cardiovascular development. Proc. Natl. Acad. Sci. U. S. A. 103:11189-11194.
64. Ko LJ, Engel JD. 1993. DNA-binding specificities of the GATA transcription factor family. Mol. Cell. Biol. 13:4011-4022.
65. Sakai Y, Nakagawa R, Sato R, Maeda M. 1998. Selection of DNA binding sites for human transcriptional regulator GATA-6. Biochem. Biophys. Res. Commun. 250:682-688.
66. Morrisey EE, Ip HS, Lu MM, Parmacek MS. 1996. GATA-6: a zinc finger transcription factor that is expressed in multiple cell lineages derived from lateral mesoderm. Dev. Biol. 177:309-322.
67. Chang DF, Belaguli NS, Iyer D, Roberts WB, Wu SP, Dong XR, Marx JG, Moore MS, Beckerle MC, Majesky MW, Schwartz RJ. 2003. Cysteine- rich LIM-only proteins CRP1 and CRP2 are potent smooth muscle differentiation cofactors. Dev. Cell 4:107-118.
68. Shirvani S, Xiang F, Koibuchi N, Chin MT. 2006. CHF1/Hey2 suppressesSM- MHCpromoter activity through an interaction with GATA-6. Biochem. Biophys. Res. Commun. 339:151-156.
69. Yin F, Herring BP. 2005. GATA-6 can act as a positive or negative regulator of smooth muscle-specific gene expression. J. Biol. Chem. 280:4745-4752.
70. Molkentin JD, Lu JR, Antos CL, Markham B, Richardson J, Robbins J, Grant SR, Olson EN. 1998. A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell 93:215-228.
71. Molkentin JD, Olson EN. 1997. GATA4: a novel transcriptional regulator of cardiac hypertrophy? Circulation 96:3833-3835.
72. van Berlo JH, Elrod JW, van den Hoogenhof MM, York AJ, Aronow BJ, Duncan SA, Molkentin JD. 2010. The transcription factor GATA-6 regulates pathological cardiac hypertrophy. Circ. Res. 107: 1032-1040.
73. Peters SL, Schmidt M, Michel MC. 2006. Rho kinase: a target for treating urinary bladder dysfunction? Trends Pharmacol. Sci. 27:492-497.
74. Su X, Stein R, Stanton MC, Zderic S, Moreland RS. 2003. Effect of partial outlet obstruction on rabbit urinary bladder smooth muscle function. Am. J. Physiol. Renal Physiol. 284:F644 -F652.